About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Kintara Therapeutics (NASDAQ: KTRA) Granted Orphan Drug Status for VAL-083 and the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)

Kintara Therapeutics, Inc. (NASDAQ: KTRA) is engaged as a biopharmaceutical company, which is focused on the research and development of innovative therapies targeting solid tumor cancers. The San Diego-based biopharma company has two late-stage, Phase 3-ready drug programs: VAL-083 for glioblastoma and REM-001 for cutaneous metastatic breast cancer (CMBC).

Shares of the oncology company are rallying 23% through afternoon trading on Thursday, December 15, 2022. Over the past three months, Kintara Therapeutics has seen average daily volume of 379,840 shares. However, volume of 393,415 shares or dollar volume of around $3.86 million, has already exchanged hands through afternoon trading.

Shares of Kintara Therapeutics are gaining after the company announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to VAL-083 for the treatment of diffuse intrinsic pontine glioma (DIPG), a rare and very aggressive childhood brain cancer.

VAL-083 is a first-in-class, small-molecule chemotherapeutic with a novel action mechanism that has demonstrated the ability to generate clinical activities in a range of cancers.

Orphan Drug Designation is a major achievement for the company, as it provides several incentives for the company, such as tax credits, development incentives, prescription drug user fee exemptions and a seven-year marketing exclusivity period upon FDA approval. The Orphan Drug program elevates drugs and innovative treatments that are meant to treat, diagnose, or prevent a rare disease that affects fewer than 200,000 people.

“This is another important step for us in evaluating VAL-083 as a treatment for brain tumors in addition to our lead indication of glioblastoma,” said Robert E. Hoffman, Kintara’s President and CEO. “We will continue with our clinical advancement of the drug candidate with our objective of delivering a much-needed new treatment that can benefit patients.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Kintara Therapeutics (NASDAQ: KTRA) Granted Orphan Drug Status for VAL-083 and the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG) appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.